Alzheimer's disease starts with a sticky protein called amyloid beta that builds up into plaques in the brain, setting off a chain of events that results in brain atrophy and cognitive decline. The new generation of Alzheimer's ...
Apr 3, 2024
0
52
University of Queensland researchers have found targeting amyloid plaque in the brain is not essential for ultrasound to deliver cognitive improvement in neurodegenerative disorders.
Apr 2, 2024
0
68
Familial Alzheimer's disease can be transferred via bone marrow transplant, researchers show in the journal Stem Cell Reports. When the team transplanted bone marrow stem cells from mice carrying a hereditary version of Alzheimer's ...
Mar 28, 2024
0
101
Researchers at the University of Leeds and Lancaster University in the UK have identified a new potential target for the treatment of Alzheimer's disease—PDE4B. Their work is published in Neuropsychopharmacology.
Mar 26, 2024
0
21
Mild cognitive impairment—an early stage of dementia—is widely underdiagnosed in people 65 and older. That is the key takeaway of two recent studies from our team.
Mar 24, 2024
0
408
A new Viewpoint article published in the Journal of the American Medical Association (JAMA), titled " Use of Lecanemab for Patients with Cardiovascular Disease—The Challenge of Uncertainty," advocates for additional research ...
Mar 18, 2024
0
1
On Jan. 31, aducanumab, a pricey drug approved for treatment of early-stage Alzheimer's disease, was withdrawn from the market. And in early March, the Food and Drug Administration delayed its decision regarding whether to ...
Mar 14, 2024
0
1
Early stages of neurodegenerative disorders are characterized by the accumulation of proteins in discrete populations of brain cells and the degeneration of these cells. For most diseases, this selective vulnerability pattern ...
Mar 11, 2024
0
2
Instead of approving the new Alzheimer's drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely by an expert panel, the drug's ...
Mar 8, 2024
0
0
Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.
Mar 8, 2024
0
10
